Almotriptan Tablet, Film Coated
Product Images NDC 27241-041

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Almotriptan (NDC 27241-041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Almotan 125mg

Almotriptan 12.5 mg tablets, USP carton label for oral film-coated tablets. The label shows a 12-tablet package with the NDC 27241-042-21, marketed by Ajanta Pharma USA Inc. and manufactured by Ajanta Pharma Limited in India. It includes storage instructions, a barcode, and emphasizes the 12.5 mg strength prominently on multiple panels.*

FDA Label Image

Almotan 625mg

Almotriptan 6.25 mg film-coated tablets packaging label for oral use. The carton features the product name, strength, dosage form, and NDC number 27241-041-11. Marketed by Ajanta Pharma USA Inc. and manufactured by Ajanta Pharma Limited in India. Storage and child safety instructions are also included on the label.*

FDA Label Image

Structure (Almotriptan Str)

Chemical structure of almotriptan. The diagram shows the molecular arrangement including a sulfonamide group, an indole moiety, and an acidic component indicating the presence of a salt form.*

FDA Label Image

Figure_01 (Figure 01)

A line graph depicting the probability of a measured outcome over hours post dose (0 to 2 hours) for almotriptan tablets at 6.25 mg and 12.5 mg doses compared to placebo. The x-axis shows hours post dose, and the y-axis shows the probability, ranging from 0 to 1. Almotriptan 12.5 mg shows the highest probability increase, followed by 6.25 mg, with placebo showing the lowest.*

FDA Label Image

Figure_02 (Figure 02)

A line graph displaying probability over time (hours post dose) for three treatment groups: placebo, almotriptan 6.25 mg tablets, and almotriptan 12.5 mg tablets. The x-axis represents hours post dose up to 24 hours, and the y-axis represents probability ranging from 0 to 1. The chart compares the response probabilities for the different doses and placebo over a 24-hour period.*

FDA Label Image

Figure_03 (Figure 03)

A line graph showing the estimated probability of response over hours post dose for placebo and almotriptan tablets at 6.25 mg and 12.5 mg strengths. The x-axis represents hours post dose (0 to 2), and the y-axis represents estimated probability of response (0 to 1). Both almotriptan doses show higher probability of response compared to placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.